Methods: This study was a multicenter, observational, retrospective follow-up study of patients who participated in the Phase III clinical trial (70 patients recruited). Auxological parameters [including height, height velocity, and their associated height standard deviation scores (HSDS)] were obtained from 39 patients. Safety was assessed by recording any adverse events (AEs). Results: In total, 27 men and 12 women provided auxological data. At the start of the follow-up study, the mean age of the patients was 12.5 ± 2.7 years, mean height was 144.8 ± 13.9 cm and mean HSDS was -1.16 ± 0.63. By the end of the follow-up period, mean height had increased to
INTRODUCTION
The availability of recombinant human growth hormone (rhGH) since the late 1980s has revolutionized the treatment and long-term prognosis of children with growth hormone deficiency (GHD) and other growth disturbances [1, 2] . In addition to nearnormalization of final height, treatment with rhGH has been shown to improve pubertal development, bone mass, and quality of life in patients with GHD [3] [4] [5] .
Currently, there are several rhGH products available for the treatment of pediatric growth disturbances. Omnitrope Ò (Sandoz) is the first product to be approved by the European Medicines Agency via the biosimilar regulatory pathway, with approval granted in 2006 on the basis of comparable quality, safety, and efficacy to the reference rhGH product (Genotropin Ò , Pfizer) [6] . Biosimilar rhGH is licensed in Europe for the treatment of growth disturbances in the following pediatric indications: GHD, Turner Syndrome, chronic renal insufficiency, PraderWilli Syndrome, and children born small for gestational age [7] . and elicited a good growth response, as demonstrated by significant increases from baseline in all auxological parameters evaluated. The safety profile of biosimilar rhGH was shown to be similar to the reference product, both in terms of adverse events (AEs) and immunogenicity [11] . This paper reports the efficacy and safety results of a long-term follow-up study of a subgroup of children with GHD treated with Omnitrope Ò in the original phase III study [11] who were monitored until they achieved their adult height.
METHODS

Study Design and Patient Population
This was an observational, retrospective, multicenter, follow-up study examining the long-term safety and efficacy of Omnitrope Ò in patients recruited to a phase III study [11] and who continued rhGH treatment under the same participating investigators. analyze data on the adult height. The secondary objectives were to ascertain the differences in height, HSDS, HV, and HV standard deviation score from when the phase III study was finalized until adult height was reached.
Treatment and Visits
The rhGH was administered subcutaneously in accordance with the Summary of Product Characteristics, the local prescribing information, and the standard clinical practice of each center. The patients continued treatment until they reached final height, or until rhGH treatment was interrupted or discontinued due to other reasons. The frequency of visits was at the discretion of the investigators; no additional or specific visits, tests, or assessments were required as part of the study.
Efficacy Assessments
Patients' height was measured at each visit, using a stadiometer (Holtain) by trained health staff and according to standard clinical practice.
HV (cm/year) and HSDS were calculated using historical height data. In addition, the projected final height (FH pro ) was defined as the height that the patient is expected to reach at the end of linear growth. In the original study, major increases in FH pro during rhGH therapy were observed for both genders: all FH pro values increased significantly when compared with the start of treatment [11] .
Safety Assessments
All AEs were recorded at each visit for the complete duration of rhGH treatment, irrespective of causality. AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), Version 14.0 or higher. [12] .
Data Collection and Analysis
RESULTS
Patients
A total of 39 patients completed this follow-up extension study and received study medication throughout. Data were available for 27 males (69.2%) and 12 females (30.8%). Thirty-eight patients had idiopathic GHD, one with multiple deficiencies.
Patient characteristics on entry to the followup study (i.e., end of the phase III trial) are shown in Table 1 There was no history of concomitant conditions, apart from two male patients (5.1%) with concomitant heart disease. All patients who initially entered the phase III study were naïve to rhGH treatment. In the initial trial, the mean (SD) duration of rhGH treatment was 3.7 (1.0) years.
Efficacy
By the end of the follow-up period, mean height had increased by ?16.7 cm from baseline (end of the phase III study; Table 2 ). In males, mean height had increased by ?18.9 cm and in females by ?11.6 cm ( Table 2 HV height velocity, SD standard deviation, SDS standard deviation score a P = 0.043 for males versus females b Percentages are calculated relative to each gender and then for the overall population (total column) c Two patients had missing data for HV
Safety
At the end of the follow-up period, most patients had discontinued treatment, mainly due to reaching adult height/physician decision. The reasons for study discontinuation are presented in Table 3 . Two male patients have still not yet reached adult height and remain in treatment at the end of this study. There were no treatmentrelated AEs reported in any of the patients enrolled in this long-term follow-up.
Treatment Switches and Dose Adjustments
During GH Therapy In the initial phase III trial, the FH pro values were an average height gain of 12-18 cm, leading to final adult height of 157.7 cm for females and 167.5 cm for males [11] . At the end of this follow-up extension study, the average height gain was 11.6 cm for females and 18.9 cm for males, and the mean adult height achieved was 157.6 cm in females and 165.5 cm While the final heights achieved by the patients in this study are lower than the current national averages, they are within the accepted 'normal' ranges for the adult Spanish population [13] . Similarly to the original 5-year study, HSDS continued to increase gradually during the first part of this follow-up study [11] . However, after 3 years HSDS started to decrease. Most of the patients followed were already decreasing their HV and all of them had achieved their peak height velocity previously.
Other factors that may have contributed to the slow down of HSDS and HV may be that some patients needed to receive a higher dose of rhGH. While the doses were increased for certain patients, perhaps more patients needed a dose increment. In addition, HSDS and HV may have slowed down as patients started to mature and reach their adult height.
Taken together, the results from this followup study demonstrate that rhGH treatment is effective and leads to notable improvements in all height parameters in children with GHD.
These findings are in line with other studies reporting that rhGH replacement therapy leads to normalization of height during childhood and also to near-normal adult height within the corresponding target range [4, 14, 15] .
Furthermore, it has been proven that rhGH has beneficial effects on body composition and metabolism throughout adult life [14, 15] .
Although during the study, 23% of patients switched to another rhGH product, due to administrative issues, the data reveal that the adult height is above the Spanish adult height average in more than 50% of subjects.
In terms of safety, there were no drug-related AEs in any patients over the course of the follow-up period. This favorable safety profile for biosimilar rhGH is also consistent with previous studies reporting a positive risk:
benefit ratio for rhGH in children with GHD [16, 17] .
This study had some inherent limitations, i.e., it was a multicenter, observational, retrospective study with a limited number of patients. The investigators were not required to perform any specific tests or evaluations as part of the study and additional data were not routinely collected. It would have been of interest to have more data on certain parameters such as parental height, age and height at the onset of puberty; duration of access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. 
